Chemoprevention of 7,12-dimethylbenz[a]anthracene (DMBA)-induced hamster cheek pouch carcinogenesis by a 5-lipoxygenase inhibitor, garcinol

Nutrition and Cancer

Volumn 64, Issue 8, 2012, Pages 1211-1218

  Chen, Xin ^a   Zhang, Xinyan ^b,c   Lu, Ye ^b   Shim, Joong Youn ^c   Sang, Shengmin ^d   Sun, Zheng ^b,e   Chen, Xiaoxin ^c  

^a CHANGZHOU UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c NORTH CAROLINA CENTRAL UNIVERSITY   (United States)

^d NORTH CAROLINA A AND T STATE UNIVERSITY   (United States)

^e CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

7,12 DIMETHYLBENZ[A]ANTHRACENE; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; ATRELEUTON; BENZOPHENONE DERIVATIVE; CURCUMIN; GARCINOL; LEUKOTRIENE B4; LICOFELONE; LIPOXYGENASE INHIBITOR; UNCLASSIFIED DRUG; ZILEUTON;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER PREVENTION; CELL PROLIFERATION; CHEEK POUCH; COMPUTER ANALYSIS; COMPUTER MODEL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SCREENING; ENZYME ACTIVITY; IC 50; MALE; MOUTH MUCOSA; MOUTH SQUAMOUS CELL CARCINOMA; NONHUMAN; PROSTAGLANDIN SYNTHESIS;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; ANTICARCINOGENIC AGENTS; CARCINOGENS; CELL PROLIFERATION; CHEEK; CRICETINAE; LEUKOTRIENE B4; LIPOXYGENASE INHIBITORS; MALE; MESOCRICETUS; MOUTH NEOPLASMS; PLANT EXTRACTS; TERPENES;

EID: 84873642549     PISSN: 01635581     EISSN: 15327914     Source Type: Journal    
DOI: 10.1080/01635581.2012.718032     Document Type: Article

References (38)

1. Magrath I and Litvak J: Cancer in developing countries: opportunity and challenge. J Natl Cancer Inst 85, 862-874, 1993.
2. Funk GF, Karnell LH, Robinson RA, Zhen WK, Trask DK, et al.: Presentation, treatment, and outcome of oral cavity cancer: a National Cancer Data Base report. Head Neck 24, 165-180, 2002.
3. Siegel R, Ward E, Brawley O, and Jemal A: Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61, 212-236, 2011.
4. Chen X, Sood S, Yang CS, Li N, and Sun Z: Five-lipoxygenase pathway of arachidonic acid metabolism in carcinogenesis and cancer chemoprevention. Curr Cancer Drug Targets 6, 613-622, 2006.
5. Li N, Sood S, Wang S, Fang M, Wang P, et al.: Overexpression of 5-lipoxygenase and cyclooxygenase 2 in hamster and human oral cancer and chemopreventive effects of zileuton and celecoxib. Clin Cancer Res 11, 2089-2096, 2005.
6. Sun Z, Sood S, Li N, Ramji D, Yang P, et al.: Involvement of the 5-lipoxygenase/leukotriene A4 hydrolase pathway in 7, 12-dimethylbenz [a]anthracene (DMBA)-induced oral carcinogenesis in hamster cheek pouch, and inhibition of carcinogenesis by its inhibitors. Carcinogenesis 27, 1902-1908, 2006.
7. Guo Y, Wang X, Zhang X, Sun Z, Chen X: Ethanol promotes chemically induced oral cancer in mice through activation of the 5-lipoxygenase pathway of arachidonic acid metabolism. Cancer Prev Res (Phila) 4, 1863-1872, 2011.
8. Li N, Chen X, Liao J, Yang G, Wang S, et al.: Inhibition of 7,12-dimethylbenz[a]anthracene (DMBA)-induced oral carcinogenesis in hamsters by tea and curcumin. Carcinogenesis 23, 1307-1313, 2002.
9. Sun Z, Guan X, Li N, Liu X, Chen X: Chemoprevention of oral cancer in animal models and human patients with Zeng Sheng Ping, a mixture of medicinal herbs. Oral Oncol 45, 105-110, 2010.
10. Yang P, Sun Z, Chan D, Cartwright CA, Vijjeswarapu M, et al.: Zyflamend reduces LTB4 formation and prevents oral carcinogenesis in a 7,12-dimethylbenz[alpha]anthracene (DMBA)-induced hamster cheek pouch model. Carcinogenesis 29, 2182-2189, 2008.
11. Sood S, Shiff SJ, Yang CS, and Chen X: Selection of topically applied nonsteroidal anti-inflammatory drugs for oral cancer chemoprevention. Oral Oncol 41, 562-567, 2005.
12. Potts RO and Guy RH: Predicting skin permeability. Pharm Res 9, 663-669, 1992.
13. Gilbert NC, Bartlett SG, Waight MT, Neau DB, Boeglin WE, et al.: The structure of human 5-lipoxygenase. Science 331, 217-219, 2011.
14. Verdonk ML, Cole JC, Hartshorn MJ, Murray CW, Taylor RD: Improved protein-ligand docking using GOLD. Proteins 52, 609-623, 2003.
15. Sang S, Pan MH, Cheng X, Bai N, Stark RE, et al.: Chemical studies on antioxidant mechanism of garcinol: analysis of radical reaction products of garcinol and their antitumor activities. Tetrahedron 57, 9931-9938, 2001.
16. Kramer I, Lucas R, Pindborg J, and Sobin L: WHO, Collaborating center for oral precancerous lesions: definitions of leukoplakia and related lesions: an aid to studies on oral precancer. Oral Surg Oral Med Oral Pathol 46, 518-589, 1978.
17. Leininger I and KJokinen M. Tumors of the oral cavity, pharynx, oesophagus and stomach. In: Pathology of Tumors in Laboratory Animals, Vol. 3, Turosov V (ed.). Albany, NY: IARC, 1982, pp. 167-169.
18. Bell RL, Harris RR, Malo PE, Bouska JB, Shaughnessy TK, et al.: ABT-761 attenuates bronchoconstriction and pulmonary inflammation in rodents. J Pharmacol Exp Ther 280, 1366-1373, 1997.
19. Alvaro-Gracia JM: Licofelone-clinical update on a novel LOX/COX inhibitor for the treatment of osteoarthritis. Rheumatology (Oxford) 43(Suppl 1), i21-i25, 2004.
20. Bakana P, Claeys M, Totte J, Pieters LA, Van Hoof L, et al.: Structure and chemotherapeutical activity of a polyisoprenylated benzophenone from the stem bark of Garcinia huillensis. J Ethnopharmacol 21, 75-84, 1987.
21. Krishnamurthy N and Lewis YS: On the structures of garcinol, isogarcinol and camboginol. Tetrahedron Lett 2, 793-796, 1981.
22. Koeberle A, Northoff H, Werz O: Identification of 5-lipoxygenase and microsomal prostaglandin E2 synthase-1 as functional targets of the antiinflammatory and anti-carcinogenic garcinol. Biochem Pharmacol 77, 1513-1521, 2009.
23. Balasubramanyam K, Altaf M, Varier RA, Swaminathan V, Ravindran A, et al.: Polyisoprenylated benzophenone, garcinol, a natural histone acetyltransferase inhibitor, represses chromatin transcription and alters global gene expression. J Biol Chem 279, 33716-33726, 2004.
24. Lenta BN, Vonthron-Senecheau C, Weniger B, Devkota KP, Ngoupayo J, et al.: Leishmanicidal and cholinesterase inhibiting activities of phenolic compounds from Allanblackia monticola and Symphonia globulifera. Molecules 12, 1548-1557, 2007.
25. Prasad S, Ravindran J, Sung B, Pandey MK, and Aggarwal BB: Garcinol potentiates TRAIL-induced apoptosis through modulation of death receptors and antiapoptotic proteins. Mol Cancer Ther 9, 856-868, 2010.
26. Shaari K, Suppaiah V, Wai LK, Stanslas J, Tejo BA, et al.: Bioassayguided identification of an anti-inflammatory prenylated acylphloroglucinol from Melicope ptelefolia and molecular insights into its interaction with 5-lipoxygenase. Bioorg Med Chem 19, 6340-6347, 2011.
27. Ahmad A, Wang Z, Ali R, Maitah MY, Kong D, et al.: Apoptosis-inducing effect of garcinol is mediated by NF-kappaB signaling in breast cancer cells. J Cell Biochem 109, 1134-1141, 2010.
28. Ahmad A, Wang Z, Wojewoda C, Ali R, Kong D, et al.: Garcinol-induced apoptosis in prostate and pancreatic cancer cells is mediated by NF-kappaB signaling. Front Biosci (Elite Ed) 3, 1483-1492, 2011.
29. Cheng AC, Tsai ML, Liu CM, Lee MF, Nagabhushanam K, et al.: Garcinol inhibits cell growth in hepatocellular carcinoma Hep3B cells through induction of ROS-dependent apoptosis. Food Funct 1, 301-307, 2010.
30. Parasramka MA and Gupta SV: Garcinol inhibits cell proliferation and promotes apoptosis in pancreatic adenocarcinoma cells. Nutr Cancer 63, 456-465, 2011.
31. Tanaka T, Kohno H, Shimada R, Kagami S, Yamaguchi F, et al.: Prevention of colonic aberrant crypt foci by dietary feeding of garcinol in male F344 rats. Carcinogenesis 21, 1183-1189, 2000.
32. Yoshida K, Tanaka T, Hirose Y, Yamaguchi F, Kohno H, et al.: Dietary garcinol inhibits 4-nitroquinoline 1-oxide-induced tongue carcinogenesis in rats. Cancer Lett 221, 29-39, 2005.
33. Lesch CA, Squier CA, Cruchley A, Williams DM, and Speight P: The permeability of human oral mucosa and skin to water. J Dent Res 68, 1345-1349, 1989.
34. Shojaei AH: Buccal mucosa as a route for systemic drug delivery: a review. J Pharm Pharm Sci 1, 15-30, 1998.
35. McCormick DL, Phillips JM, Horn TL, Johnson WD, Steele VE, et al.: Overexpression of cyclooxygenase-2 in rat oral cancers and prevention of oral carcinogenesis in rats by selective and nonselective COX inhibitors. Cancer Prev Res (Phila) 3, 73-81, 2010.
36. Matthews JB, Mason GI, Scully CM, and Prime SS: In situ characterisation of the oral mucosal inflammatory cell response of rats induced by 4-nitroquinoline-N-oxide. Carcinogenesis 7, 783-788, 1986.
37. Laufer SA, Augustin J, Dannhardt G, and Kiefer W: (6,7- Diaryldihydropyrrolizin-5-yl)acetic acids, a novel class of potent dual inhibitors of both cyclooxygenase and 5-lipoxygenase. J Med Chem 37, 1894-1897, 1994.
38. Flynn DL, Rafferty MF, and Boctor AM: Inhibition of 5- hydroxyeicosatetraenoic acid (5-HETE) formation in intact human neutrophils by naturally-occurring diarylheptanoids: inhibitory activities of curcuminoids and yakuchinones. Prostaglandins Leukot Med 22, 357-360, 1986.